Kotarosumitomo Nakayama
Overview
Explore the profile of Kotarosumitomo Nakayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kiyokawa T, Mimura K, Nagamine K, Nakayama K, Horiuchi M, Morikawa T, et al.
Int J Hematol
. 2023 Feb;
118(1):146-150.
PMID: 36797397
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is caused by anti-HPA alloantibody, and anti-HPA-4b is the most common cause in Japanese. Anti-HPA-5b is frequently detected in pregnant women, but it...
2.
Hosokawa M, Kashiwagi H, Nakayama K, Sakuragi M, Nakao M, Morikawa T, et al.
Transfusion
. 2019 Jul;
59(7):2479-2480.
PMID: 31268593
No abstract available.
3.
Nakayama K, Wakamatsu K, Fujii H, Shinzaki S, Takamatsu S, Kitazume S, et al.
J Biochem
. 2018 Nov;
165(3):227-237.
PMID: 30445455
Core fucosylation, catalysed by α-1, 6 fucosyltransferase (FUT8), regulates growth factor receptors in immune function. Although core fucose regulates many immune cell types, few reports confront the association between core...
4.
Hosokawa M, Kashiwagi H, Nakayama K, Sakuragi M, Nakao M, Morikawa T, et al.
Transfusion
. 2018 Sep;
58(12):3003-3013.
PMID: 30267414
Background: There is an increasing demand for daratumumab (DARA), an immunoglobulin (Ig)G1κ monoclonal antibody (MoAb) that recognizes CD38, to manage relapsed or refractory multiple myeloma (MM) patients. However, DARA leads...
5.
Morishita K, Ito N, Koda S, Maeda M, Nakayama K, Yoshida K, et al.
Clin Chim Acta
. 2018 Sep;
487:84-89.
PMID: 30189188
Fucosylation is one of the most important glycosylations involved in cancer and inflammation. Many studies have reported significant increases in serum fucosylated haptoglobin (Fuc-Hpt) in a variety of cancer patients....
6.
Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, et al.
World J Gastroenterol
. 2016 May;
22(17):4403-10.
PMID: 27158210
Aim: To determine the efficacy of Mac-2 binding protein (Mac-2bp) for diagnosis of chronic pancreatitis. Methods: Fifty-nine healthy volunteers (HV), 162 patients with chronic pancreatitis (CP), and 94 patients with...
7.
Ueda M, Kamada Y, Takamatsu S, Shimomura M, Maekawa T, Sobajima T, et al.
Pancreatology
. 2016 Feb;
16(2):238-43.
PMID: 26897254
Background/objectives: Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all malignancies, and its diagnosis in early stages is the most important prognostic factor. Chronic pancreatitis (CP), a common background...
8.
Shimomura M, Nakayama K, Azuma K, Terao N, Nishino K, Takamatsu S, et al.
Clin Chim Acta
. 2015 Apr;
446:30-6.
PMID: 25861849
Background: Fucosylated haptoglobin (Fuc-Hpt) is a novel cancer biomarker that increases in various pathological conditions. We previously established a Fuc-Hpt lectin-antibody assay using Aleuria aurantia lectin (AAL), and applied this...
9.
Terao N, Takamatsu S, Minehira T, Sobajima T, Nakayama K, Kamada Y, et al.
World J Gastroenterol
. 2015 Apr;
21(13):3876-87.
PMID: 25852272
Aim: To evaluate/isolate cancer stem cells (CSCs) from tissue or cell lines according to various definitions and cell surface markers. Methods: Lectin microarray analysis was conducted on CSC-like fractions of...
10.
Kiyokawa T, Koh Y, Mimura K, Nakayama K, Hosokawa M, Sakuragi M, et al.
Int J Hematol
. 2014 Jun;
100(4):398-401.
PMID: 24972694
Neonatal alloimmune thrombocytopenia (NAIT) is induced by maternal alloantibodies raised against fetal platelet antigens inherited from the paternal parent. In contrast to Caucasians, in Asians, predominantly in Japanese, most frequently...